Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perillic Acid (-) SCHEMBL19341659 | 1.00 | TSHR (1.00) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| Perillic Acid SCHEMBL19341660 | 1.00 | TSHR (1.00) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| Perillic Acid SCHEMBL8434974 | 1.00 | TSHR (1.00) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL13301247 | 0.87 | TSHR (0.77) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL14626987 | 0.87 | TSHR (0.77) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL8591960 | 0.83 | TSHR (0.71) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL8591050 | 0.83 | TSHR (0.71) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL6683680 | 0.81 | TSHR (0.69) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL6684800 | 0.81 | TSHR (0.69) | TSHRLMNATRPA1ALDH1A1ALOX15 | |
| SCHEMBL8280195 | 0.81 | TSHR (0.69) | TSHRLMNATRPA1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1075 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712792-A1 | A NOVEL FEED COMPOSITION | DSM IP Assets B.V. (NL) | 2026-03-25 | — | — | EP | claimed |
| WO-2026044024-A1 | COMPOSITIONS COMPRISING COMBINATIONS OF PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF AMYLIN ANALOG, AND USES THEREOF | I2O THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260041095-A1 | A PRESERVATION METHOD | ANALYTICON DISCOVERY ZWEIGNIEDERLASSUNG DER BRAIN BIOTECH AG (DE) | 2026-02-12 | — | — | US | claimed |
| US-20260034044-A1 | A PRESERVATIVE COMPOSITION | ANALYTICON DISCOVERY ZWEIGNIEDERLASSUNG DER BRAIN BIOTECH AG (DE) | 2026-02-05 | — | — | US | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4619578-A2 | MODIFIED FIBRE MATERIAL | Wenatex Forschung - Entwicklung - Produktion GmbH (AT) | 2025-09-24 | — | — | EP | claimed |
| EP-4619459-A1 | MODIFIED PU FOAM | Wenatex Forschung - Entwicklung - Produktion GmbH (AT) | 2025-09-24 | — | — | EP | claimed |
| US-20250248400-A1 | NANOPARTICULATE FORMULATION FOR PREVENTING OR TREATING CALLOSE FORMATION IN PLANTS | PURDUE RESEARCH FOUNDATION (US) | 2025-08-07 | — | — | US | claimed |
| US-20250249108-A1 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-08-07 | — | — | US | claimed |
| EP-4565065-A1 | A PRESERVATION METHOD | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-06-11 | — | — | EP | claimed |
| US-6423742-B1 | SYNERGISTIC MIXTURE OF LIMONENE AND GALLIC ACID | LARSON DRAKE (US) | 2002-07-23 | — | — | US | claimed |
| US-20020010128-A1 | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism | CELLEGY PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001078706-A2 | TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY AND RELATED MUCOCUTANEOUS DISORDERS USING INHIBITORS OF MEVALONATE SYNTHESIS AND METABOLISM | CELLEGY PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2001015593-A2 | COMPOSITIONS FOR REDUCING VASCULAR PLAQUE FORMATION AND METHODS OF USING SAME | LARSON DRAKE (US) | 2001-03-08 | — | — | WO | claimed |
| CN-1203886-A | Method for producing hydrogen sulfide | TANG PEISI (CN) | 1999-01-06 | — | — | CN | claimed |
| EP-0727987-A4 | INHIBITION OF RESPIRATORY BURST USING POSTTRANSLATIONAL MODIFICATION INHIBITORS | SCRIPPS RESEARCH INST (US) | 1998-03-11 | — | — | EP | claimed |
| US-5688673-A | GENETIC ENGINEERING OF PLASMIDS USING BACILLUS TO FORM DNA SEGMENTS AND CONVERTING LIMONENE TO MONOTERPENE | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1997-11-18 | — | — | US | claimed |
| EP-0727987-A1 | INHIBITION OF RESPIRATORY BURST USING POSTTRANSLATIONAL MODIFICATION INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-08-28 | — | — | EP | claimed |
| US-5244916-A | INHIBITION OF RESPIRATORY BURST USING POSTTRANSLATIONAL MODIFICATION INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-09-14 | — | — | US | claimed |
| WO-1993014749-A1 | INHIBITION OF RESPIRATORY BURST USING POSTTRANSLATIONAL MODIFICATION INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041095-A1 | A PRESERVATION METHOD | LSS, ASAH2, CUTA | TSHR 3361/4885LMNA 341/4885TRPA1 1868/4885 |
| US-20260034044-A1 | A PRESERVATIVE COMPOSITION | ERG28, FOXO3, DEGS1 | TSHR 1111/4885LMNA 206/4885TRPA1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.